Related by context. All words. (Click for frequent words.) 69 castrate resistant 68 refractory colorectal cancer 68 metastatic bladder 68 Gleevec resistant 68 castrate resistant prostate cancer 68 unresectable tumors 67 Prognostic factors 67 prostate cancer CRPC 67 antiangiogenic therapy 67 castration resistant 67 pancreatic adenocarcinoma 67 endocrine therapies 67 BRCA deficient 66 hormone deprivation 66 refractory prostate cancer 66 gefitinib Iressa 66 refractory Hodgkin 66 castration resistant prostate cancer 66 metastatic gastric 66 tumor histology 66 EGFR inhibitors 66 nonmetastatic 66 Graft Versus Host 66 Acute myeloid leukemia 66 imatinib Gleevec ® 66 malignant pleural mesothelioma 65 cytoreduction 65 LHRH receptor positive 65 mRCC 65 resistant hormone refractory 65 minimally symptomatic 65 EGFR TKI 65 CTAP# Capsules 65 medically inoperable 65 K ras mutations 65 seminoma 65 Metastatic breast cancer 65 secondary hyperparathyroidism 65 stage IIIB 65 CYT# potent vascular disrupting 65 metastatic colorectal 65 tumors GIST 65 tumor subtypes 65 metastatic renal 65 cytotoxic therapy 65 mycosis fungoides 65 prostate cancer CaP 65 hepatocellular cancer 65 HBeAg negative 65 nonalcoholic steatohepatitis NASH 65 Hepatocellular Carcinoma HCC 65 urothelial bladder cancer 65 imatinib therapy 65 Anthracycline 65 EGFR mutation positive 65 relapsed leukemia 65 epithelial tumors 65 relapsed SCLC 65 diabetic kidney 64 T#I [002] 64 antiangiogenic agent 64 leukemia AML 64 metastatic renal cell 64 Surgical resection 64 T1c 64 chemoresistant 64 Chronic pancreatitis 64 HER2 positive metastatic breast 64 trastuzumab Herceptin ® 64 EGFR tyrosine kinase inhibitor 64 recurrent glioblastoma multiforme 64 completely resected 64 HNSCC 64 ADPKD 64 taxane chemotherapy administered 64 metastatic renal cell carcinoma 64 resectable 64 castration resistant hormone refractory 64 biliary tract cancer 64 hematopoietic cancers 64 heavily pretreated 64 precursor lesions 64 basal cell carcinoma BCC 64 small molecule tyrosine 64 erlotinib Tarceva 64 differentiated thyroid 64 recurrent metastatic 64 antibody MAb 64 recurrent ovarian 64 dasatinib Sprycel 64 metastatic malignant melanoma 64 stage IIIB IV 64 refractory ovarian cancer 64 ErbB2 positive 64 elacytarabine 64 relapsed AML 64 cirrhosis liver failure 64 receptor tyrosine kinase inhibitor 64 malignant ascites 64 metastatic castration resistant 64 RhuDex R 64 dasatinib Sprycel ® 64 androgen independent 64 renal carcinoma 64 surgical debulking 63 refractory metastatic 63 cervical lymph nodes 63 MAGE A3 ASCI 63 seminomas 63 taxane therapy 63 gastric adenocarcinoma 63 remission induction 63 relapsed ovarian cancer 63 prostate carcinoma 63 peritoneal carcinomatosis 63 precancerous condition 63 Carcinoid tumors 63 anti angiogenic agents 63 myelodysplastic myeloproliferative diseases 63 metastatic hormone refractory 63 gastrointestinal stromal tumors GIST 63 alkylating agent 63 LHRH analogues 63 hematological malignancy 63 allogeneic HSCT 63 Cutaneous T 63 lymphoid malignancies 63 relapsing remitting MS RRMS 63 prognostic indicator 63 curative resection 63 neoadjuvant chemotherapy 63 epithelial ovarian cancer 63 Temsirolimus 63 Campath alemtuzumab 63 recurrent glioblastoma 63 imatinib Gleevec 63 Adjuvant therapy 63 ovarian carcinoma 63 deCODE ProstateCancer TM 63 Basal cell 63 KRAS mutation 63 anthracycline containing 63 acute GvHD 63 histologic subtype 63 pre malignant lesions 63 urothelial carcinoma 63 tyrosine kinase inhibitors TKIs 63 paclitaxel poliglumex 63 CCR9 antagonist 63 IRX 2 63 androgen deprivation 63 operable breast cancer 63 relapsed MM 63 androgen ablation 63 octreotide implant 63 anti angiogenic therapy 63 erlotinib Tarceva ® 63 metastatic malignant 63 refractory chronic myeloid 63 Chronic lymphocytic leukemia CLL 63 leukemia CLL 63 skeletal metastases 63 metastatic kidney 63 Virulizin ® 62 recurrent NSCLC 62 fluoropyrimidine 62 selectively inhibited 62 Glioblastoma Multiforme 62 TroVax ® 62 OvaRex R 62 invasive carcinoma 62 Atypical Hemolytic Uremic Syndrome 62 cervical carcinoma 62 polycythemia vera essential thrombocythemia 62 HER2 positive breast 62 Naive Patients 62 fallopian tube carcinoma 62 transplantation HCT 62 metastatic pancreatic 62 cisplatin resistant 62 LHRH agonists 62 IMA# 62 PANVAC VF 62 LymphoStat B belimumab 62 bone metastasis 62 trastuzumab DM1 62 hormonal therapies 62 OncoVAX ® 62 precancerous tissues 62 Chronic lymphocytic leukemia 62 riociguat 62 indolent follicular non 62 hormone receptor status 62 nucleoside analog 62 adjuvant cisplatin 62 essential thrombocythemia ET 62 neoadjuvant therapy 62 Stage IIB 62 Myelodysplastic Syndrome MDS 62 lumiliximab 62 Degarelix 62 IGF IR 62 Bezielle 62 Aflibercept 62 hormonally responsive 62 clinically localized prostate 62 Adjuvant chemotherapy 62 myelofibrosis polycythemia vera 62 fibrotic disease 62 liver scarring 62 advanced metastatic prostate 62 Prostatic 62 Telatinib 62 demonstrated antitumor activity 62 hormonally sensitive 62 indolent lymphomas 62 superficial bladder cancer 62 Papillary 62 Erlotinib 62 treating neuropathic pain 62 orchitis 62 EGFR tyrosine kinase inhibitors 62 antimetabolite 62 Metastatic 62 systemic fungal infections 62 chemopreventive agent 62 Archexin 62 Treg cell 62 ATTR CM 62 SHPT 62 HER2 expression 62 Ophena TM 62 curative therapy 62 lymphoid organs 62 kidney urologic 62 humanised monoclonal antibody 62 breast carcinoma 62 luteinizing hormone releasing 62 metastatic sarcomas 62 androgen receptor AR 62 YONDELIS 62 refractory acute myeloid 62 imatinib resistance 62 kinase inhibition 62 p# deficient 62 pT2 62 metaglidasen 62 hepatic fibrosis 62 GISTs 62 oral prodrug 62 induced anemia 62 KRAS oncogene 62 Natalizumab 62 neoplasias 62 Xanafide 62 CMV infections 62 IV NSCLC 62 Hodgkin lymphoma HL 62 immune dysregulation 62 novel VDA molecule 62 squamous cell carcinoma SCC 62 liver metastasis 61 including eniluracil ADH 61 radiation sensitizer 61 Laquinimod 61 virally induced 61 Trastuzumab 61 denileukin diftitox 61 Pemetrexed 61 FUSILEV enhances 61 proliferative disorders 61 DCVax R 61 vinca alkaloid 61 immunomodulatory therapy 61 AGILECT R 61 HER2 positivity 61 BRAF inhibitors 61 Relapsed Refractory 61 Testosterone deficiency 61 Pegylated Interferon 61 Alemtuzumab 61 HER2 negative 61 EOquin 61 pancreatic lung 61 carcinoid 61 estramustine 61 HER2 overexpression 61 hepatocellular carcinomas 61 hypereosinophilic syndrome 61 Hormone Refractory Prostate Cancer 61 PCNSL 61 induce remission 61 pulmonary metastases 61 TTR amyloidosis 61 taxane chemotherapy 61 SSc 61 MDS AML 61 gastric atrophy 61 smoldering myeloma 61 sentinel lymph node biopsy 61 invasive lobular carcinoma 61 pituitary adenomas 61 KRAS status 61 mCRPC 61 myeloproliferative diseases 61 cell lymphoma CTCL 61 SNT MC# 61 TRAIL induced apoptosis 61 prognostic markers 61 haematologic 61 IV metastatic melanoma 61 lymphomas leukemias 61 localized renal 61 T2DM 61 metastatic RCC 61 paclitaxel Taxol R 61 malignant pleural mesothelioma MPM 61 Nilotinib 61 Pharmacokinetics PK 61 Peginterferon alfa 2b 61 alvespimycin 61 chronic eosinophilic leukemia 61 HER2 positive 61 alkylating agents 61 steroid refractory 61 MyVax R 61 pancreatic colon 61 Tyrosine Kinase Inhibitors 61 KRAS mutant 61 bladder carcinoma 61 Radical prostatectomy 61 PNP inhibitor 61 Alequel 61 taxane refractory 61 pemphigus vulgaris 61 corticosteroid dexamethasone 61 signal transduction inhibitors 61 adriamycin 61 selective modulator 61 ovarian endometrial 61 Polycythemia vera 61 Irinotecan 61 GRNOPC1 contains 61 gastric carcinoma 61 Onalta ™ 61 Soft Tissue Sarcoma 61 Cloretazine 61 Myelodysplastic syndromes MDS 61 lichen planus 61 trabectedin 61 prostate cancer HRPC 61 pharmacologic intervention 61 Ceflatonin 61 squamous cell lung cancer 61 chronic thromboembolic pulmonary 61 ELACYT 61 Squamous cell 61 potent inducer 61 NPM1 mutation 61 Bleomycin 61 gemcitabine Gemzar ® 61 HER2 positive cancers 61 predictive biomarkers 61 breast pancreatic 61 Leukemias 61 benign prostatic hypertrophy BPH 61 VitiGam 61 Telintra 61 AA Amyloidosis 61 pediatric acute lymphoblastic 61 NMIBC 61 abnormal pap smears 61 virotherapy 61 hematological parameters 61 androgen receptor antagonist 61 histologies 61 Clusterin 61 previously untreated follicular 61 mCRC patients 61 triphendiol 61 Pegloticase 61 vidofludimus 61 colorectal cancer liver metastases 61 EndoTAGTM 1 61 unresectable stage 61 Cloretazine ® 61 non metastatic osteosarcoma 61 RhuDex ® 61 pancreatic NET 61 HCV protease inhibitors 61 Kinoid 61 leiomyomas 61 relapsed ALL 61 cervical lesions 61 Carcinoma 61 dirucotide MBP# 61 IV melanoma 61 Voreloxin 61 cisplatin chemotherapy 61 Aplidin 61 refractory chronic lymphocytic 61 Disease Progression 61 generation purine nucleoside 61 Chronic Myeloid Leukemia CML 61 Sudhir Agrawal D.Phil 61 nodal metastasis 61 malignant transformation 61 Kamada AAT 61 pancreatic carcinoma 61 adjuvant therapies 61 pelvic malignancies 61 antimetabolites 61 carcinoid tumors 61 thalidomide Thalomid 61 underwent resection 61 radiotherapy RT 61 leukemia multiple myeloma 61 evaluating picoplatin 61 Cell Lymphoma CTCL 61 gastrointestinal stromal tumors GISTs 61 antimitotic 61 Sezary syndrome 61 TACI Ig 61 mutated KRAS gene 61 Factor Receptor 61 endometrial hyperplasia 60 cisplatin gemcitabine 60 Fludara ® 60 ZOLINZA 60 AA amyloidosis 60 EGFR pathway 60 anti EGFR antibody 60 Interferon beta 60 breast endometrial 60 treat chronic sinusitis 60 Chronic myeloid leukemia 60 Akt activation 60 SPRYCEL ® 60 intra arterial chemotherapy 60 bleomycin 60 taxane resistant 60 MET amplification 60 budesonide foam 60 follicular Non Hodgkin 60 huC# DM4 60 Trastuzumab DM1 60 Follicular lymphoma 60 Belldegrun 60 prognostic biomarker 60 gastrointestinal stromal tumor 60 colorectal carcinoma 60 BZL# 60 ALN TTR 60 Squamous 60 Fludarabine 60 liposomal formulation 60 grade cervical intraepithelial 60 bladder ovarian 60 Panzem R NCD 60 Epratuzumab 60 adenomatous polyps 60 adjuvant tamoxifen 60 Progressive Multifocal Leukoencephalopathy 60 Pralatrexate 60 advanced metastatic renal 60 Onconase 60 BCG refractory 60 EGFR mutation 60 mutant KRAS 60 Myelodysplastic Syndrome 60 metastatic androgen independent 60 Riluzole 60 indolent NHL 60 Malignant Melanoma 60 chemosensitivity 60 docetaxel Taxotere ® 60 mutated K ras 60 Troxatyl 60 DHFR 60 gastrointestinal stromal tumors 60 adverse cytogenetics 60 antiestrogen therapy 60 colon carcinoma 60 cholangiocarcinoma 60 advanced hepatocellular carcinoma 60 adjuvant radiotherapy 60 antiestrogen 60 immunocompetent adults 60 Castration Resistant Prostate Cancer 60 chemoradiotherapy 60 Endometrial cancer 60 histologically confirmed 60 Familial Adenomatous Polyposis 60 HRPC 60 PAOD 60 Gleevec imatinib mesylate 60 SERMs 60 thetreatment 60 preoperative chemotherapy 60 pancreatic insufficiency 60 ALK inhibitor 60 Phase #/#a trial 60 endometrial cancers 60 Phase #b/#a clinical 60 alefacept 60 tumor subtype 60 chemotherapy cisplatin 60 OvaRex ® MAb 60 hPAM4 60 pediatric malignancies 60 nonsmall cell lung cancer 60 chronic granulomatous disease 60 Ph + acute lymphoblastic 60 OHR/AVR# 60 systemic anaplastic large 60 acute myelogenous leukemia AML 60 premalignant 60 Lenalidomide 60 efaproxiral 60 anaplastic 60 Hsp# inhibition 60 gastric cardia 60 Medullary thyroid cancer 60 mapatumumab 60 anti angiogenic drugs 60 Simulect 60 locoregional 60 Zolinza 60 Vidaza azacitidine 60 situ CIS 60 therapeutic armamentarium 60 HGS ETR1 60 forodesine 60 progesterone receptor negative 60 locoregional recurrence 60 CYP#D# genotype 60 Mantle Cell Lymphoma 60 prostate adenocarcinoma 60 Glioblastoma multiforme GBM 60 RNAi therapeutic targeting 60 recurrent glioma 60 myeloablative 60 platinum refractory 60 Factor VIIa 60 genomic biomarker 60 tumor lysis syndrome 60 BRAF V# mutation 60 papillary renal cell carcinoma 60 HBV vaccine 60 Her2 positive 60 GW# [003] 60 Kit CD# positive 60 smoldering multiple myeloma 60 HIV coinfected 60 ceroid lipofuscinosis NCL 60 AML acute myeloid 60 lung fibrosis 60 Unresectable 60 cell carcinoma RCC 60 treating peripheral arterial 60 neoadjuvant treatment 60 K ras gene 60 Metastatic Melanoma 60 PROSTVAC VF 60 bony metastases 60 p#HER# positive 60 Adjuvant Treatment 60 Gleevec imatinib 60 bacillus Calmette Guerin 60 dyskeratosis congenita 60 MGUS 60 HIV HCV coinfected 60 paclitaxel Taxol 60 PCA3 gene 60 E#F# 60 HER2 positive breast cancer 60 Achieves Primary Endpoint 60 pT3 60 GIST tumors 60 chimeric monoclonal antibody 60 polyomavirus nephropathy 60 vemurafenib 60 G#DT 60 follicular non 60 immune modulating 60 Bosutinib 60 Hsp# Inhibitor 60 progression TTP 60 Chronic Lymphocytic Leukemia CLL 60 IMiDs ® 60 Proxinium TM 60 briakinumab 60 interstitial cystitis IC 60 surgically resectable 60 stage IIIb IV 60 Fulvestrant 60 recurrent glioblastoma multiforme GBM 60 Immunotherapeutic 60 multiple myeloma MM 60 metastatic neuroendocrine tumors 60 palliative radiotherapy 60 acute leukemias 60 PEGylated anti 60 erythema nodosum 60 vascular disrupting agent 60 neutropenic patients 60 PSMA ADC 60 accumulate preferentially 60 malignant phenotype 60 Ozarelix 60 Patients Treated With 60 SinuNase TM 60 ixabepilone 60 novel emulsion formulation 60 histological subtype 60 precancerous cervical lesions 60 uterine fibroids endometriosis 60 XYOTAX TM 60 prognostic indicators 60 prognostic marker 60 metastatic castrate resistant 60 FLT3 60 immunodeficiency disorders 60 small lymphocytic lymphoma 60 sarcomatoid 60 Squalamine 60 Aviptadil 60 ATL# [001] 60 Acute myeloid leukemia AML 60 Hedgehog inhibitor 60 Symadex 60 Neoadjuvant 60 TKI therapy 60 Acute Coronary Syndromes ACS 60 premalignant lesion 60 cabazitaxel 60 Doxil ® 60 cells multiply uncontrollably 60 anthracyclines taxanes 60 idiopathic myelofibrosis 60 ISTODAX 60 antifungal therapy 60 Abiraterone acetate 59 Temodar ® 59 Opportunistic infections 59 aromatase inhibitors AIs 59 panobinostat 59 huN# DM1 59 clinically heterogeneous 59 investigational monoclonal antibody 59 antiproliferative effects 59 Diffuse Large B 59 radiation chemoradiation 59 Roche Herceptin 59 virologic responses 59 Metastases 59 relapsed acute myelogenous 59 cutaneous T 59 androgen ablation therapy 59 antiandrogens 59 non resectable metastatic 59 Actinic Keratosis 59 Chemoradiation 59 decompensated cirrhosis 59 herpetic keratitis 59 underlying pathophysiology 59 AEG# 59 concurrent chemoradiation 59 lupus nephritis 59 targeted radiotherapeutic 59 Bortezomib 59 leukemia APL 59 breast carcinomas 59 benign prostatic hyperplasia enlarged 59 intravenous cyclophosphamide 59 IMC #B 59 BPH benign prostatic 59 Immunosuppressive 59 oral picoplatin 59 rALLy 59 inflammatory demyelinating 59 urothelial cancer 59 Lymphocytic 59 Mucositis 59 Myelofibrosis 59 systemic amyloidosis 59 K RAS 59 lobular carcinoma 59 Granulocyte Colony Stimulating Factor 59 trans retinoic acid 59 TransMID TM 59 Sipuleucel T 59 anticancer therapy 59 trastuzumab Herceptin R 59 idarubicin 59 vaginal candidiasis 59 PEGylated Fab fragment 59 antibody mediated 59 coinfected patients 59 interferon therapy 59 adjuvant therapy 59 specific antigen PSA 59 chemo resistant 59 neuroendocrine cancers 59 OMNARIS HFA 59 hormone LHRH antagonist 59 acetonide FA 59 curable cancers 59 nilotinib Tasigna ® 59 Bcr Abl T#I mutation 59 AAG geldanamycin analog 59 Gliomas 59 BRAF V#E mutation 59 neovascular diseases 59 EGFR mutation status 59 pancreatic islet cell 59 Hurthle cell 59 cetuximab Erbitux ® 59 clonogenic 59 BARACLUDE ® 59 VEGF inhibitors 59 Velcade bortezomib 59 LEUKINE 59 Leydig cell 59 IDH mutations 59 undergoing radical prostatectomy 59 BRAF mutant 59 glutamic acid decarboxylase 59 myeloid metaplasia 59 HuLuc# 59 apoptosis induced 59 MYCN amplification 59 RET PTC rearrangements 59 lymphoma leukemia 59 LPLD 59 Lymph node 59 Decitabine 59 palifermin 59 targeting PCSK9 59 MGd 59 metastatic uveal melanoma 59 Cytarabine 59 autologous transplants 59 Renal Cell Carcinoma RCC 59 T1a 59 pelvic lymphadenectomy 59 stage IIIA 59 metastatic adenocarcinoma 59 mTOR inhibitors 59 histone deacetylase inhibitor 59 EVIZON TM 59 Smac mimetics 59 Advaxis Phase 59 PSADT 59 chronic HCV 59 K ras mutation 59 MYLOTARG 59 mutated BRAF gene 59 muscular dystrophy cystic fibrosis 59 Letairis ambrisentan 59 Systemic lupus erythematosus 59 ovarian lung 59 anti mitotic 59 Interferon Beta 59 Tectin TM 59 PCa 59 adjuvant radiation 59 recurrent GBM 59 Genasense ® 59 Colon polyps 59 pancreatic endocrine 59 Interferon alpha 59 enzastaurin 59 refractory NSCLC 59 multitargeted 59 Intravenous CP 59 Aggrastat ® tirofiban hydrochloride 59 leukemia ALL 59 malignant pheochromocytoma 59 Acute Myeloid Leukaemia AML 59 transgene expression 59 recurrent epithelial ovarian 59 potent antiproliferative 59 p# inhibitor 59 chronic hepatitis cirrhosis 59 prostate cancer PCa 59 hormone refractory prostate cancer 59 cytoreductive nephrectomy 59 methotrexate therapy 59 Epigenomics proprietary 59 Onrigin 59 Dasatinib 59 medullary thyroid cancer 59 Renal Cell Carcinoma 59 refractory indolent non 59 docetaxel Injection Concentrate 59 Ribavirin causes 59 metastatic sarcoma 59 malignant cancerous 59 Advanced Melanoma 59 regorafenib 59 Mitomycin C 59 noninfectious uveitis 59 antitumor effect 59 ara C 59 KIACTA ™ 59 Gastrointestinal Stromal Tumors 59 Capecitabine 59 ovarian suppression 59 Cardiotoxicity 59 GvHD 59 metastatic ovarian cancer 59 dysplastic lesions caused 59 prognostically 59 interleukin IL -# 59 Prodarsan 59 Urocidin 59 anthracycline taxane 59 membranous nephropathy 59 NPM1 mutations 59 lorvotuzumab mertansine 59 antiangiogenic agents 59 fibroadenomas 59 chronic myeloid 59 basiliximab 59 Tumor Necrosis Factor 59 Metastatic colorectal cancer 59 Azacitidine 59 Prednisone Against Refractory 59 immunosuppressive regimen 59 situ LCIS 59 natriuretic peptide 59 p# biomarkers 59 premalignant lesions 59 doublet chemotherapy 59 Annamycin 59 Vandetanib 59 Relapsed Refractory Multiple Myeloma 59 CFTR inhibitors 59 epigenetic therapies 59 sorafenib Nexavar 59 Teverelix 59 Gefitinib 59 relapsed multiple myeloma 59 FOLFOX6 59 TNF blocker therapy 59 B7 H3 59 perioperatively 59 tigecycline 59 liver metastases 59 mutated KRAS 59 Phase #b/#a trial 59 myeloproliferative disorder 59 Benign breast 59 pharmacokinetic PK study 59 irinotecan containing 59 Amgen Neulasta ® 59 Diabetic nephropathy 59 immunosuppressive regimens 59 late onset Pompe 59 pharmacokinetic interactions 59 gemcitabine Gemzar 59 gastrointestinal stromal tumor GIST 59 Estrogen Receptor 59 VP# [004] 59 choroidal neovascularization 59 liposomal doxorubicin 59 Previously Treated 59 vosaroxin 59 Meets Primary Endpoint 59 TTF Therapy 59 Cimzia TM 59 Vidofludimus 59 standard chemotherapy regimen 59 Hervé Hoppenot President 59 Bronchiectasis 59 hepatocellular carcinoma liver 59 Octreolin 59 candidates Azedra TM 59 EGFR expressing mCRC 59 oral clodronate 59 Toxicities 59 abnormal lymphocytes 59 prostate carcinomas 59 immunomodulation 59 Peginterferon 59 CINTREDEKIN BESUDOTOX 59 Testicular cancer 59 essential thrombocythemia 59 Epidermal Growth Factor Receptor 59 IL# PE#QQR 59 acadesine 59 chlamydial infection 59 lymphoma CTCL 59 Enzastaurin 59 vinca alkaloids 59 Benign prostatic hyperplasia BPH 59 Philadelphia Chromosome Positive 59 EBRT 59 PITX2 methylation 59 goserelin 59 neoplasia 59 galiximab 59 Urocidin TM 59 tanespimycin 59 chronic myelogenous leukemia CML 59 nucleoside naive 58 phase IIb study 58 PEGylated interferon 58 TBC# 58 null responder 58 myelofibrosis MF 58 nasopharyngeal carcinoma 58 HLA DR4 58 cytotoxic therapies 58 clinicopathological features 58 neuroendocrine tumors 58 pancreatic neuroendocrine tumors 58 ductal breast cancer 58 durable remissions 58 Arranon 58 HGS ETR2 58 refractory AML 58 recurrent herpes labialis 58 KRAS wild 58 Cholangiocarcinoma 58 cediranib 58 APOPTONE 58 Endometrial 58 non resectable liver 58 oral JAK1 58 Pazopanib 58 prostate cancer mCRPC 58 Tyrima 58 nucleoside analogue 58 lymphocytic leukemia 58 myelodysplastic syndrome MDS 58 recombinant erythropoietin 58 papillary thyroid carcinoma 58 oxaliplatin Eloxatin 58 ALK inhibitors 58 alpha1 antitrypsin deficiency 58 secondary amenorrhea 58 Idiopathic Pulmonary Fibrosis 58 Follicular Lymphoma 58 CDP# 58 antihormonal 58 PEGylated interferon beta 1a 58 mycophenolate 58 FLT3 mutations 58 presymptomatic 58 dual endothelin receptor antagonist 58 CINQUIL 58 phase IIb clinical 58 EGS# 58 Paraplatin ® 58 immunotherapeutic approaches 58 hepatitis C HCV 58 radiochemotherapy 58 hypoparathyroidism 58 psoriasis rheumatoid arthritis 58 LHRH antagonists 58 Antitumor Activity 58 Epstein Barr Virus 58 fibrocystic disease 58 anemias 58 systemic mastocytosis 58 Lung transplantation 58 DEB# 58 EGFR mutations 58 MVA MUC1 IL2 58 MYDICAR ® 58 Aromatase 58 mucinous 58 BCR ABL inhibitors 58 debilitating autoimmune 58 nonmelanoma 58 invasive aspergillosis 58 CMV vaccine 58 carcinoma HCC 58 BEXXAR Therapeutic Regimen 58 alpha interferons 58 sunitinib Sutent 58 tumor necrosis 58 pulmonary hypertension PH 58 CYC# 58 KRAS mutant tumors 58 Triapine 58 CVBT #H 58 colorectal liver metastases 58 MCSP respectively 58 Taxol ® 58 immunosuppressed 58 Tumour Vascular Disrupting Agent 58 locoregional disease 58 angiogenesis inhibition 58 immuno modulatory 58 node metastases 58 conventional DMARDs